Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Pharmacology of Infectious Diseases

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1544714

Icarisid Ⅱ modulates mitochondrial dynamics for anti-HBV activity

Provisionally accepted
Zhengyun Liu Zhengyun Liu 1Haiyan Yang Haiyan Yang 1Juan Wen Juan Wen 1Dongyan Xiao Dongyan Xiao 1,2Wan Yu Wan Yu 1Guo Luo Guo Luo 1Qihai Gong Qihai Gong 3Huan Wang Huan Wang 1*
  • 1 Key Laboratory of infectious disease & Biosafety, Provincial Department of Education, Zunyi Medical University, Guizhou, China, Zunyi, China
  • 2 Department of Basic Teaching, Zunyi Medical and Pharmaceutical College, Guizhou, China, Zunyi, China
  • 3 Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Guizhou, China., Zunyi, China

The final, formatted version of the article will be published soon.

    Introduction: To investigate the potential anti-hepatitis B virus (HBV) activity of Icariside Ⅱ (ICS Ⅱ), and elucidate its underlying mitochondrial dynamics mechanisms.The study employed in vivo and in vitro assays to evaluate anti-HBV effects of ICS Ⅱ. An HBV replicating mouse model was established through hydrodynamic injection of pAAV/HBV1.2, the impact of ICS Ⅱ on HBV replication and liver toxicity was assessed. In vitro cell-based assays used HBV-positive HepG2.2.15 cells. Cytotoxicity was determined with CCK-8 assay, while ELISA and qPCR were employed to measure HBsAg, HBeAg, and HBV DNA levels. The livers of ICS II-treated HBV-infected mice were taken for transcriptome sequencing to screen for different genes, and the results were verified by Western Blot.Mitochondrial morphology and dynamics were visualized using confocal imaging and transmission electron microscopy. Key protein expressions related to mitochondrial fission and fusion were analyzed via WB. Intracellular ROS generation was assessed using fluorescence staining.The study found that ICS Ⅱ exhibited significant anti-HBV effects both in vivo and in vitro. The results of RNA-Seq indicated that ICS Ⅱ modulated the mRNA levels of Fisl, a protein associated with mitochondrial dynamics, during the anti-HBV response. It induced mitochondrial fragmentation and enhanced mitochondrial motility in HBV-positive cells. Notably, key proteins associated with mitochondrial fission and fusion demonstrated alterations favoring fission. Furthermore, ICS Ⅱ effectively reduced ROS production in HBV-positive cells.ICS Ⅱ exhibits significant anti-HBV potential through its regulation of mitochondrial dynamics and ROS production.

    Keywords: Hepatitis B virus, HepG2.2.15 cell, mitochondrial dynamic, ROS - reactive oxygen species, icarisid II

    Received: 13 Dec 2024; Accepted: 28 Feb 2025.

    Copyright: © 2025 Liu, Yang, Wen, Xiao, Yu, Luo, Gong and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Huan Wang, Key Laboratory of infectious disease & Biosafety, Provincial Department of Education, Zunyi Medical University, Guizhou, China, Zunyi, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more